These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy. Levite M J Neural Transm (Vienna); 2014 Aug; 121(8):1029-75. PubMed ID: 25081016 [TBL] [Abstract][Full Text] [Related]
7. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders. Lipton SA J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S61-74. PubMed ID: 15665416 [TBL] [Abstract][Full Text] [Related]
8. Inflammatory mediators leading to protein misfolding and uncompetitive/fast off-rate drug therapy for neurodegenerative disorders. Lipton SA; Gu Z; Nakamura T Int Rev Neurobiol; 2007; 82():1-27. PubMed ID: 17678953 [TBL] [Abstract][Full Text] [Related]
9. NMDA Receptors Containing the GluN2D Subunit Control Neuronal Function in the Subthalamic Nucleus. Swanger SA; Vance KM; Pare JF; Sotty F; Fog K; Smith Y; Traynelis SF J Neurosci; 2015 Dec; 35(48):15971-83. PubMed ID: 26631477 [TBL] [Abstract][Full Text] [Related]
10. GRIN2B gain of function mutations are sensitive to radiprodil, a negative allosteric modulator of GluN2B-containing NMDA receptors. Mullier B; Wolff C; Sands ZA; Ghisdal P; Muglia P; Kaminski RM; André VM Neuropharmacology; 2017 Sep; 123():322-331. PubMed ID: 28533163 [TBL] [Abstract][Full Text] [Related]
11. Investigation of the structural requirements for N-methyl-D-aspartate receptor positive and negative allosteric modulators based on 2-naphthoic acid. Irvine MW; Fang G; Sapkota K; Burnell ES; Volianskis A; Costa BM; Culley G; Collingridge GL; Monaghan DT; Jane DE Eur J Med Chem; 2019 Feb; 164():471-498. PubMed ID: 30622023 [TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationships and pharmacophore model of a noncompetitive pyrazoline containing class of GluN2C/GluN2D selective antagonists. Acker TM; Khatri A; Vance KM; Slabber C; Bacsa J; Snyder JP; Traynelis SF; Liotta DC J Med Chem; 2013 Aug; 56(16):6434-56. PubMed ID: 23909910 [TBL] [Abstract][Full Text] [Related]
14. Benzimidazolone bioisosteres of potent GluN2B selective NMDA receptor antagonists. Lütnant I; Schepmann D; Wünsch B Eur J Med Chem; 2016 Jun; 116():136-146. PubMed ID: 27061977 [TBL] [Abstract][Full Text] [Related]
15. NMDA receptors control vagal afferent excitability in the nucleus of the solitary tract. Vance KM; Rogers RC; Hermann GE Brain Res; 2015 Jan; 1595():84-91. PubMed ID: 25446446 [TBL] [Abstract][Full Text] [Related]
16. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Lipton SA Curr Alzheimer Res; 2005 Apr; 2(2):155-65. PubMed ID: 15974913 [TBL] [Abstract][Full Text] [Related]
17. Direct pharmacological monitoring of the developmental switch in NMDA receptor subunit composition using TCN 213, a GluN2A-selective, glycine-dependent antagonist. McKay S; Griffiths NH; Butters PA; Thubron EB; Hardingham GE; Wyllie DJ Br J Pharmacol; 2012 Jun; 166(3):924-37. PubMed ID: 22022974 [TBL] [Abstract][Full Text] [Related]